<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(1)</volume><submitter>Muller A</submitter><pubmed_abstract>Contrast enhancement of glioblastomas (GBM) is caused by the decrease in relaxation time, T1. Here, we demonstrate that the quantitative measurement of T1 (qT1) discovers a subtle enhancement in GBM patients that is invisible in standard MRI. We assessed the volume change of this "cloudy" enhancement during radio-chemotherapy and its impact on patients' progression-free survival (PFS). We enrolled 18 GBM patients in this observational, prospective cohort study and measured 3T-MRI pre- and post contrast agent with standard T1-weighted (T1w) and with sequences to quantify T1 before radiation, and at 6-week intervals during radio-chemotherapy. We measured contrast enhancement by subtracting pre from post contrast contrast images, yielding relative signal increase ∆T1w and relative T1 shorteni</pubmed_abstract><journal>Cancer medicine</journal><pagination>89-99</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5269700</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.</pubmed_title><pmcid>PMC5269700</pmcid><pubmed_authors>Ditter P</pubmed_authors><pubmed_authors>Jurcoane A</pubmed_authors><pubmed_authors>Glas M</pubmed_authors><pubmed_authors>Muller A</pubmed_authors><pubmed_authors>Madler B</pubmed_authors><pubmed_authors>Kebir S</pubmed_authors><pubmed_authors>Hattingen E</pubmed_authors><pubmed_authors>Herrlinger U</pubmed_authors><pubmed_authors>Tzaridis T</pubmed_authors><pubmed_authors>Schrader F</pubmed_authors><pubmed_authors>Schild HH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.</name><description>Contrast enhancement of glioblastomas (GBM) is caused by the decrease in relaxation time, T1. Here, we demonstrate that the quantitative measurement of T1 (qT1) discovers a subtle enhancement in GBM patients that is invisible in standard MRI. We assessed the volume change of this "cloudy" enhancement during radio-chemotherapy and its impact on patients' progression-free survival (PFS). We enrolled 18 GBM patients in this observational, prospective cohort study and measured 3T-MRI pre- and post contrast agent with standard T1-weighted (T1w) and with sequences to quantify T1 before radiation, and at 6-week intervals during radio-chemotherapy. We measured contrast enhancement by subtracting pre from post contrast contrast images, yielding relative signal increase ∆T1w and relative T1 shorteni</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Jan</publication><modification>2025-04-26T12:15:18.124Z</modification><creation>2019-03-27T02:35:04Z</creation></dates><accession>S-EPMC5269700</accession><cross_references><pubmed>27891815</pubmed><doi>10.1002/cam4.966</doi></cross_references></HashMap>